DAPA-CKD [39] showed that dapagliflozin, another SGLT-2 inhibitor, reduces kidney and cardiovascular events in chronic kidney disease patients with and without T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.